The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy
Background Human epidermal growth factor receptor 2 (HER2) overexpression was associated with locoregional recurrence (LRR) in the preadjuvant trastuzumab era. This study aimed to examine the effect of trastuzumab on LRR in mastectomy patients and whether it varied with postmastectomy radiation (PMR...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2015-08, Vol.22 (8), p.2517-2525 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2525 |
|---|---|
| container_issue | 8 |
| container_start_page | 2517 |
| container_title | Annals of surgical oncology |
| container_volume | 22 |
| creator | Lanning, Ryan M. Morrow, Monica Riaz, Nadeem McArthur, Heather L. Dang, Chau Moo, Tracy-Ann El-Tamer, Mahmoud Krause, Kate Siu, Chun Hsu, Meier Zhang, Zhigang Pei, Xin McCormick, Beryl Powell, Simon N. Ho, Alice |
| description | Background
Human epidermal growth factor receptor 2 (HER2) overexpression was associated with locoregional recurrence (LRR) in the preadjuvant trastuzumab era. This study aimed to examine the effect of trastuzumab on LRR in mastectomy patients and whether it varied with postmastectomy radiation (PMRT).
Methods
From the authors’ institutional database, 501 women with stages I–III HER2-positive breast cancer who underwent mastectomy from 1998 to 2007 were identified. A landmark analysis was performed to compare two cohorts: 170 women who received trastuzumab and 281 who did not. Kaplan–Meier methods were used to estimate locoregional recurrence-free survival (LRRFS). A propensity score analysis was used to balance the treatment groups with respect to multiple covariates. Analogous methods were used to study the effect of PMRT.
Results
The women in the trastuzumab group were more likely to be node positive and to receive systemic therapy or PMRT (
p
|
| doi_str_mv | 10.1245/s10434-014-4321-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1701337045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3764003931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-f1303f8c38b53e409cd8208f8cd0877f53327f84f90f3ab74e79d187eca668d23</originalsourceid><addsrcrecordid>eNp1kc9uFDEMxiMEoqXwAFxQJC5cBvJ3kj2W1bZFWgRCyznKZpx2VjuTJcm0Kk_C4-JhC0JInGzZP3-2_BHykrO3XCj9rnCmpGoYV42SgjfiETnlGiuqtfwx5qy1zUK0-oQ8K2XHGDeS6afkRGjdKt6aU_JjcwN0FSOESlOk591uuvVjpZvsS52-T4Pf0jTSdQopw3WfRr-nXyBMOcMYYB65Qmakq0PfQR6we5nTXb2hFz7UlGcWDnMims-p9LW_Bfo-A4rTpUeFjJvAV-joXY9TH7GBp6Th_jl5Ev2-wIuHeEa-Xqw2y6tm_enyw_J83QSlRG0il0xGG6TdagmKLUJnBbNY6Zg1JmophYlWxQWL0m-NArPouDUQfNvaTsgz8uaoe8jp2wSluqEvAfZ7P0KaiuOGcSkNUxrR1_-guzRl_MgvigmDX22R4kcq5FRKhugOuR98vnecudk2d7TNoW1uts3NR7x6UJ62A3R_Jn77hIA4AgVb4zXkv1b_V_UnFL6jTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1700275566</pqid></control><display><type>article</type><title>The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Lanning, Ryan M. ; Morrow, Monica ; Riaz, Nadeem ; McArthur, Heather L. ; Dang, Chau ; Moo, Tracy-Ann ; El-Tamer, Mahmoud ; Krause, Kate ; Siu, Chun ; Hsu, Meier ; Zhang, Zhigang ; Pei, Xin ; McCormick, Beryl ; Powell, Simon N. ; Ho, Alice</creator><creatorcontrib>Lanning, Ryan M. ; Morrow, Monica ; Riaz, Nadeem ; McArthur, Heather L. ; Dang, Chau ; Moo, Tracy-Ann ; El-Tamer, Mahmoud ; Krause, Kate ; Siu, Chun ; Hsu, Meier ; Zhang, Zhigang ; Pei, Xin ; McCormick, Beryl ; Powell, Simon N. ; Ho, Alice</creatorcontrib><description>Background
Human epidermal growth factor receptor 2 (HER2) overexpression was associated with locoregional recurrence (LRR) in the preadjuvant trastuzumab era. This study aimed to examine the effect of trastuzumab on LRR in mastectomy patients and whether it varied with postmastectomy radiation (PMRT).
Methods
From the authors’ institutional database, 501 women with stages I–III HER2-positive breast cancer who underwent mastectomy from 1998 to 2007 were identified. A landmark analysis was performed to compare two cohorts: 170 women who received trastuzumab and 281 who did not. Kaplan–Meier methods were used to estimate locoregional recurrence-free survival (LRRFS). A propensity score analysis was used to balance the treatment groups with respect to multiple covariates. Analogous methods were used to study the effect of PMRT.
Results
The women in the trastuzumab group were more likely to be node positive and to receive systemic therapy or PMRT (
p
< 0.01). The 5-year LRRFS was 98 % in the trastuzumab troup versus 94 % in the no trastuzumab group [hazard ratio (HR) 0.31; 95 % confidence interval (CI) 0.09
–
1.09;
p
= 0.07]. After adjustment for multiple covariates, including receipt of chemotherapy and PMRT, trastuzumab decreased LRR rates (HR 0.21; 95 % CI 0.04–0.94;
p
= 0.04). Among the women who received PMRT, trastuzumab reduced the 5-year LRR rate (0 vs 5 %;
p
= 0.06). Among those who did not receive PMRT, trastuzumab did not significantly decrease LRR (3 vs 6 %;
p
= 0.26).
Conclusion
High rates of locoregional control (5-year rate, 98 %) were observed among patients who received trastuzumab and mastectomy ± PMRT. Trastuzumab decreased LRR in HER2-positive women who received mastectomy and PMRT, suggesting that the largest benefit is seen in a higher-risk subset of patients.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-014-4321-2</identifier><identifier>PMID: 25564167</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Breast Neoplasms - chemistry ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Breast Oncology ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Humans ; Lymphatic Metastasis ; Mastectomy ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - prevention & control ; Oncology ; Radiotherapy, Adjuvant ; Receptor, ErbB-2 - analysis ; Surgery ; Surgical Oncology ; Trastuzumab - therapeutic use ; Young Adult</subject><ispartof>Annals of surgical oncology, 2015-08, Vol.22 (8), p.2517-2525</ispartof><rights>Society of Surgical Oncology 2014</rights><rights>Society of Surgical Oncology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-f1303f8c38b53e409cd8208f8cd0877f53327f84f90f3ab74e79d187eca668d23</citedby><cites>FETCH-LOGICAL-c442t-f1303f8c38b53e409cd8208f8cd0877f53327f84f90f3ab74e79d187eca668d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-014-4321-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-014-4321-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25564167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanning, Ryan M.</creatorcontrib><creatorcontrib>Morrow, Monica</creatorcontrib><creatorcontrib>Riaz, Nadeem</creatorcontrib><creatorcontrib>McArthur, Heather L.</creatorcontrib><creatorcontrib>Dang, Chau</creatorcontrib><creatorcontrib>Moo, Tracy-Ann</creatorcontrib><creatorcontrib>El-Tamer, Mahmoud</creatorcontrib><creatorcontrib>Krause, Kate</creatorcontrib><creatorcontrib>Siu, Chun</creatorcontrib><creatorcontrib>Hsu, Meier</creatorcontrib><creatorcontrib>Zhang, Zhigang</creatorcontrib><creatorcontrib>Pei, Xin</creatorcontrib><creatorcontrib>McCormick, Beryl</creatorcontrib><creatorcontrib>Powell, Simon N.</creatorcontrib><creatorcontrib>Ho, Alice</creatorcontrib><title>The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
Human epidermal growth factor receptor 2 (HER2) overexpression was associated with locoregional recurrence (LRR) in the preadjuvant trastuzumab era. This study aimed to examine the effect of trastuzumab on LRR in mastectomy patients and whether it varied with postmastectomy radiation (PMRT).
Methods
From the authors’ institutional database, 501 women with stages I–III HER2-positive breast cancer who underwent mastectomy from 1998 to 2007 were identified. A landmark analysis was performed to compare two cohorts: 170 women who received trastuzumab and 281 who did not. Kaplan–Meier methods were used to estimate locoregional recurrence-free survival (LRRFS). A propensity score analysis was used to balance the treatment groups with respect to multiple covariates. Analogous methods were used to study the effect of PMRT.
Results
The women in the trastuzumab group were more likely to be node positive and to receive systemic therapy or PMRT (
p
< 0.01). The 5-year LRRFS was 98 % in the trastuzumab troup versus 94 % in the no trastuzumab group [hazard ratio (HR) 0.31; 95 % confidence interval (CI) 0.09
–
1.09;
p
= 0.07]. After adjustment for multiple covariates, including receipt of chemotherapy and PMRT, trastuzumab decreased LRR rates (HR 0.21; 95 % CI 0.04–0.94;
p
= 0.04). Among the women who received PMRT, trastuzumab reduced the 5-year LRR rate (0 vs 5 %;
p
= 0.06). Among those who did not receive PMRT, trastuzumab did not significantly decrease LRR (3 vs 6 %;
p
= 0.26).
Conclusion
High rates of locoregional control (5-year rate, 98 %) were observed among patients who received trastuzumab and mastectomy ± PMRT. Trastuzumab decreased LRR in HER2-positive women who received mastectomy and PMRT, suggesting that the largest benefit is seen in a higher-risk subset of patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Breast Oncology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Mastectomy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Oncology</subject><subject>Radiotherapy, Adjuvant</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Trastuzumab - therapeutic use</subject><subject>Young Adult</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc9uFDEMxiMEoqXwAFxQJC5cBvJ3kj2W1bZFWgRCyznKZpx2VjuTJcm0Kk_C4-JhC0JInGzZP3-2_BHykrO3XCj9rnCmpGoYV42SgjfiETnlGiuqtfwx5qy1zUK0-oQ8K2XHGDeS6afkRGjdKt6aU_JjcwN0FSOESlOk591uuvVjpZvsS52-T4Pf0jTSdQopw3WfRr-nXyBMOcMYYB65Qmakq0PfQR6we5nTXb2hFz7UlGcWDnMims-p9LW_Bfo-A4rTpUeFjJvAV-joXY9TH7GBp6Th_jl5Ev2-wIuHeEa-Xqw2y6tm_enyw_J83QSlRG0il0xGG6TdagmKLUJnBbNY6Zg1JmophYlWxQWL0m-NArPouDUQfNvaTsgz8uaoe8jp2wSluqEvAfZ7P0KaiuOGcSkNUxrR1_-guzRl_MgvigmDX22R4kcq5FRKhugOuR98vnecudk2d7TNoW1uts3NR7x6UJ62A3R_Jn77hIA4AgVb4zXkv1b_V_UnFL6jTQ</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Lanning, Ryan M.</creator><creator>Morrow, Monica</creator><creator>Riaz, Nadeem</creator><creator>McArthur, Heather L.</creator><creator>Dang, Chau</creator><creator>Moo, Tracy-Ann</creator><creator>El-Tamer, Mahmoud</creator><creator>Krause, Kate</creator><creator>Siu, Chun</creator><creator>Hsu, Meier</creator><creator>Zhang, Zhigang</creator><creator>Pei, Xin</creator><creator>McCormick, Beryl</creator><creator>Powell, Simon N.</creator><creator>Ho, Alice</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150801</creationdate><title>The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy</title><author>Lanning, Ryan M. ; Morrow, Monica ; Riaz, Nadeem ; McArthur, Heather L. ; Dang, Chau ; Moo, Tracy-Ann ; El-Tamer, Mahmoud ; Krause, Kate ; Siu, Chun ; Hsu, Meier ; Zhang, Zhigang ; Pei, Xin ; McCormick, Beryl ; Powell, Simon N. ; Ho, Alice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-f1303f8c38b53e409cd8208f8cd0877f53327f84f90f3ab74e79d187eca668d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Breast Oncology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Mastectomy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Oncology</topic><topic>Radiotherapy, Adjuvant</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Trastuzumab - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanning, Ryan M.</creatorcontrib><creatorcontrib>Morrow, Monica</creatorcontrib><creatorcontrib>Riaz, Nadeem</creatorcontrib><creatorcontrib>McArthur, Heather L.</creatorcontrib><creatorcontrib>Dang, Chau</creatorcontrib><creatorcontrib>Moo, Tracy-Ann</creatorcontrib><creatorcontrib>El-Tamer, Mahmoud</creatorcontrib><creatorcontrib>Krause, Kate</creatorcontrib><creatorcontrib>Siu, Chun</creatorcontrib><creatorcontrib>Hsu, Meier</creatorcontrib><creatorcontrib>Zhang, Zhigang</creatorcontrib><creatorcontrib>Pei, Xin</creatorcontrib><creatorcontrib>McCormick, Beryl</creatorcontrib><creatorcontrib>Powell, Simon N.</creatorcontrib><creatorcontrib>Ho, Alice</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanning, Ryan M.</au><au>Morrow, Monica</au><au>Riaz, Nadeem</au><au>McArthur, Heather L.</au><au>Dang, Chau</au><au>Moo, Tracy-Ann</au><au>El-Tamer, Mahmoud</au><au>Krause, Kate</au><au>Siu, Chun</au><au>Hsu, Meier</au><au>Zhang, Zhigang</au><au>Pei, Xin</au><au>McCormick, Beryl</au><au>Powell, Simon N.</au><au>Ho, Alice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>22</volume><issue>8</issue><spage>2517</spage><epage>2525</epage><pages>2517-2525</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Human epidermal growth factor receptor 2 (HER2) overexpression was associated with locoregional recurrence (LRR) in the preadjuvant trastuzumab era. This study aimed to examine the effect of trastuzumab on LRR in mastectomy patients and whether it varied with postmastectomy radiation (PMRT).
Methods
From the authors’ institutional database, 501 women with stages I–III HER2-positive breast cancer who underwent mastectomy from 1998 to 2007 were identified. A landmark analysis was performed to compare two cohorts: 170 women who received trastuzumab and 281 who did not. Kaplan–Meier methods were used to estimate locoregional recurrence-free survival (LRRFS). A propensity score analysis was used to balance the treatment groups with respect to multiple covariates. Analogous methods were used to study the effect of PMRT.
Results
The women in the trastuzumab group were more likely to be node positive and to receive systemic therapy or PMRT (
p
< 0.01). The 5-year LRRFS was 98 % in the trastuzumab troup versus 94 % in the no trastuzumab group [hazard ratio (HR) 0.31; 95 % confidence interval (CI) 0.09
–
1.09;
p
= 0.07]. After adjustment for multiple covariates, including receipt of chemotherapy and PMRT, trastuzumab decreased LRR rates (HR 0.21; 95 % CI 0.04–0.94;
p
= 0.04). Among the women who received PMRT, trastuzumab reduced the 5-year LRR rate (0 vs 5 %;
p
= 0.06). Among those who did not receive PMRT, trastuzumab did not significantly decrease LRR (3 vs 6 %;
p
= 0.26).
Conclusion
High rates of locoregional control (5-year rate, 98 %) were observed among patients who received trastuzumab and mastectomy ± PMRT. Trastuzumab decreased LRR in HER2-positive women who received mastectomy and PMRT, suggesting that the largest benefit is seen in a higher-risk subset of patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25564167</pmid><doi>10.1245/s10434-014-4321-2</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2015-08, Vol.22 (8), p.2517-2525 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1701337045 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Breast Neoplasms - chemistry Breast Neoplasms - pathology Breast Neoplasms - therapy Breast Oncology Chemotherapy, Adjuvant Disease-Free Survival Female Humans Lymphatic Metastasis Mastectomy Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - prevention & control Oncology Radiotherapy, Adjuvant Receptor, ErbB-2 - analysis Surgery Surgical Oncology Trastuzumab - therapeutic use Young Adult |
| title | The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A02%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20Adjuvant%20Trastuzumab%20on%20Locoregional%20Recurrence%20of%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive%20Breast%20Cancer%20Treated%20with%20Mastectomy&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Lanning,%20Ryan%20M.&rft.date=2015-08-01&rft.volume=22&rft.issue=8&rft.spage=2517&rft.epage=2525&rft.pages=2517-2525&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-014-4321-2&rft_dat=%3Cproquest_cross%3E3764003931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1700275566&rft_id=info:pmid/25564167&rfr_iscdi=true |